summari downgrad share ew equal weight
overweight believ gap sapien low risk
indic new growth driver lead deceler
top-line growth contract multipl continu
bullish certain long-term pipelin opportun
asymptomat aortic stenosi tricuspid regurgit
opportun wont contribut materi least ew
nearest pipelin opportun pascal transcathet mitral valv
repair devic less bullish pascal
adopt transcathet mitral valv therapi occur
slowli expect clinician appear satisfi
abt new fourth gener mitraclip dilig suggest
like prevail us pascal patent litig could
potenti keep pascal us market ew
lever compani coverag univers on-going clinic trial
delay trial due coronaviru increas gap
sapien low risk approv new growth driver
top tavr royalti expir april
contribut pre-tax incom per year
lastli recent data somewhat concern
clinician believ overhang investor
see three year data next year lower price target
assum ep estim
pictur transcathet mitral valv opportun
develop slower initi expect base
feedback clinician believ transcathet mitral valv
market develop slowli investor expect
mainli one two recent outcom studi mitra-fr
neg recal coapt mitra-fr
studi present medic confer studi
compar abt mitraclip medic manag patient
function mitral regurgit fmr howev subtl
differ patient popul like lead
differ result given mitra-fr conduct franc
coapt conduct mainli
transcathet mitral valv therapi treat fmr lower
europ compar us ew reiter expect
transcathet mitral tricuspid therapi reach
howev skeptic base clinician feedback
us enthusiasm
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
clinician feedback pascal mute initi clinician hope ew pascal would
advanc abt mitraclip pascal could independ grasp mitral valv leaflet
howev sinc iter mitraclip new gener version incorpor independ
leaflet grasp clinician recent spoken seem less enthusiast pascal today
compar year ago think reduc enthusiasm contribut lower-than-expect
tmtt transcathet mitral tricuspid therapi sale ew past year ew appear
work new version pascal ace unclear close market
dilig suggest ew pascal like found infring abt patent thu far ew
pascal found infring abt patent uk switzerland recal march court
england rule edward pascal infring two abbott european patent mitraclip court
also indic would issu injunct use pascal except situat
mitraclip implant alreadi tri fail solv problem accord patent
consult big win abbott result yet anoth sign abbott prevail similar
patent us well view pleas refer prior research note abt/ew pascal uk rule
read-through us detail believ ew could settl litig saw
ew ew think less motiv settl
us pascal trial recent delay summer due coronaviru two german trial
also delay current model tmtt sale ew pascal
increas compar consensu respect
data mix result ew-sponsor studi
present march virtual on-line late break trial session american
colleg cardiolog recal one year result show ew sapien superior
surgic aortic valv replac savr primari endpoint death stroke
rehospit year result longer show still superior savr
primari endpoint numer death stroke arm savr arm
year addit rate valv thrombosi year significantli higher
arm compar savr arm vs base convers
physician expect data impact patient decis undergo tavr near-term
howev think data rais concern among clinician long-term durabl
transcathet aortic valv replac tavr gener would expect ew present
data
ew current conduct plan start pivot trial expect coronaviru
delay trial seen compani expect coronaviru result delay
ew on-going plan pivot trial on-going pivot trial includ early-tavr
function mitral regurgit clasp ii tr addit coronaviru delay start
sapien pivot trial ew indic call averag expect coronaviru
delay trial two quarter delay import increas gap
sapien low risk approv next major catalyst figur present statu ew
on-going plan pivot trial
royalti expir tavr royalti ew receiv current per
quarter expir april royalti contribut pre-tax incom
believ mani investor forgotten royalti expir sinc compani settl
despit coronaviru neg pascal uk rule mix data
valuat remain rel high ew share versu
coverag univers averag sinc peak februari despit neg rule
march pascal uk unfavor data studi ew share current
trade in-lin forward premium toward high end
forward absolut price-to-earnings multipl consensu estim think pascal
litig risk lack catalyst next year limit potenti multipl expans
figur statu ew on-going pivot trial
figur month forward price-to-earnings ratio ew price close
figur ew histor month forward price-to-earnings premium price close
productstudypriorupd estim clinicaltri govpotenti us launchtavrsapien idestart pivot trial within month tavrcomplet enrol primari endpoint reach per clinicaltri govcomplet enrol result like primari complet date iidcomplet enrol end enrol primari complet date iifenrollingenrollingestim primari complet date enrol ii trenrollingenrollingestim primari complet date feasibl studi feasibl studi estim base potenti delay coronavirussourc compani report secur llc estimatesstatu medic technolog
price target
price target assum ep estim risk includ
greater share loss model delay mitral program neg clinic data
believ ew growth slow multipl contract next year low risk
tavr opportun becom penetr next major pipelin product pascal launch
least late earli addit less bullish ew transcathet mitral valv
repair devic pascal market competit ip concern
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
